Cas no 887593-45-5 ((2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine)
(2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine Chemical and Physical Properties
Names and Identifiers
-
- (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YLMETHYL)-HYDRAZINE
- 2,3-dihydro-1,4-benzodioxin-6-ylmethylhydrazine
- Hydrazine,[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-
- (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine
- 887593-45-5
- CS-0286982
- AKOS009264992
- DTXSID70651821
- EN300-271552
- [(2,3-Dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine
- ((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine
-
- MDL: MFCD07786367
- Inchi: 1S/C9H12N2O2/c10-11-6-7-1-2-8-9(5-7)13-4-3-12-8/h1-2,5,11H,3-4,6,10H2
- InChI Key: OUJFGTIJJZPUCS-UHFFFAOYSA-N
- SMILES: O1CCOC2C=CC(CNN)=CC1=2
Computed Properties
- Exact Mass: 180.089877630g/mol
- Monoisotopic Mass: 180.089877630g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 13
- Rotatable Bond Count: 2
- Complexity: 166
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: nothing
- Topological Polar Surface Area: 56.5?2
(2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1357652-50mg |
((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine |
887593-45-5 | 98% | 50mg |
¥18446.00 | 2024-04-26 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1357652-100mg |
((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine |
887593-45-5 | 98% | 100mg |
¥16562.00 | 2024-04-26 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1357652-250mg |
((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine |
887593-45-5 | 98% | 250mg |
¥20179.00 | 2024-04-26 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1357652-500mg |
((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine |
887593-45-5 | 98% | 500mg |
¥18057.00 | 2024-04-26 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1357652-1g |
((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)hydrazine |
887593-45-5 | 98% | 1g |
¥23511.00 | 2024-04-26 | |
| Enamine | EN300-271552-0.05g |
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine |
887593-45-5 | 0.05g |
$468.0 | 2023-09-11 | ||
| Enamine | EN300-271552-0.1g |
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine |
887593-45-5 | 0.1g |
$490.0 | 2023-09-11 | ||
| Enamine | EN300-271552-0.25g |
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine |
887593-45-5 | 0.25g |
$513.0 | 2023-09-11 | ||
| Enamine | EN300-271552-0.5g |
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine |
887593-45-5 | 0.5g |
$535.0 | 2023-09-11 | ||
| Enamine | EN300-271552-1.0g |
[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]hydrazine |
887593-45-5 | 1g |
$0.0 | 2023-06-06 |
(2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine Related Literature
-
Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
-
Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
-
Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
-
Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
-
Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
Additional information on (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine
Comprehensive Overview of (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine (CAS No. 887593-45-5)
(2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine (CAS No. 887593-45-5) is a specialized organic compound that has garnered significant attention in pharmaceutical and agrochemical research due to its unique structural properties. The compound features a benzodioxin core, which is known for its stability and versatility in synthetic applications. Researchers are particularly interested in its potential as a building block for developing novel therapeutics and biologically active molecules. Its hydrazine moiety further enhances its reactivity, making it a valuable intermediate in organic synthesis.
In recent years, the demand for heterocyclic compounds like (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine has surged, driven by advancements in drug discovery and material science. This compound is often explored for its potential applications in central nervous system (CNS) drug development, given the benzodioxin scaffold's prevalence in neuroactive agents. Additionally, its methylhydrazine group offers opportunities for derivatization, enabling the creation of targeted molecules with enhanced bioavailability and selectivity.
The synthesis of 887593-45-5 typically involves multi-step organic reactions, including condensation and reduction processes. Its purity and stability are critical for ensuring reproducible results in research settings. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize this compound. Researchers also emphasize the importance of optimizing reaction conditions to minimize byproducts and improve yield, which is a recurring topic in organic chemistry forums and scientific publications.
From an industrial perspective, (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine is often discussed in the context of green chemistry and sustainable synthesis. With growing environmental concerns, scientists are exploring eco-friendly catalysts and solvents to produce this compound efficiently. This aligns with broader trends in pharmaceutical manufacturing, where reducing waste and energy consumption is a top priority. Such innovations are frequently highlighted in patent filings and conference presentations, reflecting the compound's commercial relevance.
Another area of interest is the compound's potential role in cancer research. Preliminary studies suggest that derivatives of 887593-45-5 may exhibit antiproliferative activity, sparking investigations into their mechanisms of action. While these findings are still in early stages, they underscore the compound's versatility and its promise in addressing unmet medical needs. This has led to increased searches for benzodioxin-based therapeutics and hydrazine derivatives in oncology across academic and industry databases.
In summary, (2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine (CAS No. 887593-45-5) represents a compelling subject of study due to its structural features and diverse applications. Its relevance spans drug discovery, material science, and sustainable chemistry, making it a focal point for researchers worldwide. As scientific inquiries continue to evolve, this compound is likely to remain at the forefront of innovation in synthetic and medicinal chemistry.
887593-45-5 ((2,3-dihydro-1,4-benzodioxin-6-yl)methylhydrazine) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)